36 related articles for article (PubMed ID: 7053830)
1. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract][Full Text] [Related]
2. Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies.
Naymagon L; Mascarenhas J
Hemasphere; 2017 Dec; 1(1):e1. PubMed ID: 31723730
[TBL] [Abstract][Full Text] [Related]
3. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
Kc D; Falchi L; Verstovsek S
Ann Hematol; 2017 Oct; 96(10):1595-1604. PubMed ID: 28808761
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for myelofibrosis.
Gu L; Su L; Chen Q; Xie J; Wu G; Yan Y; Liang B; Tan J; Tang N
Exp Ther Med; 2013 Mar; 5(3):927-931. PubMed ID: 23408184
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Ostojic A; Vrhovac R; Verstovsek S
Ther Clin Risk Manag; 2012; 8():95-103. PubMed ID: 22399854
[TBL] [Abstract][Full Text] [Related]
6. New drugs for the treatment of myelofibrosis.
Mesa RA
Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
[TBL] [Abstract][Full Text] [Related]
7. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan.
Shimoda K; Shide K; Kamezaki K; Okamura T; Harada N; Kinukawa N; Ohyashiki K; Niho Y; Mizoguchi H; Omine M; Ozawa K; Haradaa M
Int J Hematol; 2007 May; 85(4):338-43. PubMed ID: 17483079
[TBL] [Abstract][Full Text] [Related]
8. The therapy of myelofibrosis: targeting pathogenesis.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():296-304. PubMed ID: 12430941
[TBL] [Abstract][Full Text] [Related]
9. Clonal analysis of agnogenic myeloid metaplasia.
Kreipe H; Jaquet K; Felgner J; Parwaresch MR
Leuk Lymphoma; 1992 Dec; 8(6):459-64. PubMed ID: 1363649
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival.
Besa EC; Nowell PC; Geller NL; Gardner FH
Cancer; 1982 Jan; 49(2):308-13. PubMed ID: 7053830
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
Djordjevic V; Dencic-Fekete M; Jovanovic J; Bizic S; Jankovic G; Bogdanovic A; Cemerikic-Martinovic V; Gotic M
Cancer Genet Cytogenet; 2007 Feb; 173(1):57-62. PubMed ID: 17284371
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia.
Reilly JT
Semin Oncol; 2005 Aug; 32(4):359-64. PubMed ID: 16202681
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic differences between bone marrow and spleen in a case of agnogenic myeloid metaplasia developing blast crisis.
Brandt L; Mitelman F; Panani A
Scand J Haematol; 1975 Oct; 15(3):187-91. PubMed ID: 1198061
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic studies in twelve patients with primary myelofibrosis and myeloid metaplasia.
Smadja N; Krulik M; de Gramont A; Sirinelli A; Brissaud P; Dray C; Audebert AA; Debray J
Cancer Genet Cytogenet; 1987 Jan; 24(1):151-8. PubMed ID: 3466667
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
